Last reviewed · How we verify

Placebo matching Metformin XR

AstraZeneca · Phase 3 active Small molecule

This is a placebo formulation designed to match the appearance and administration profile of Metformin XR for use as a control in clinical trials.

This is a placebo formulation designed to match the appearance and administration profile of Metformin XR for use as a control in clinical trials. Used for Control arm in phase 3 clinical trials of Metformin XR.

At a glance

Generic namePlacebo matching Metformin XR
SponsorAstraZeneca
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Placebo matching Metformin XR contains no active pharmaceutical ingredient and serves as a blinded control comparator in phase 3 trials. It is formulated to be indistinguishable from the active Metformin XR drug in terms of appearance, taste, and release characteristics, enabling proper randomized controlled trial design. This allows researchers to isolate the true effects of Metformin XR from placebo effects.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: